ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1828

Avascular Necrosis Is Associated with APOL1 Variants in African Americans with Systemic Lupus Erythematosus

Kevin Yip1, Elizaveta Efuni 2, Yingzhi Qian 1, Robert Clancy 3, Jill Buyon 2 and Ashira Blazer 1, 1New York University School of Medicine, New York City, 2New York University School of Medicine, New York, NY, 3New York University School of Medicine, New York

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: African-Americans, Avascular necrosis, genetics and bone disease, Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: 3S082: SLE – Clinical II: Flares & Morbidity of SLE (1824–1829)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: African Americans (AA) with systemic lupus erythematous (SLE) are at higher risk for both renal disease and avascular necrosis (AVN). The two Apolipoprotein L1 (APOL1) risk variants (RV), G1 and G2, have been associated with chronic kidney disease and atherosclerosis in AAs and are responsible for excess renal risk in this population. We therefore investigated the association between carriers of the risk variants and prevalence of AVN in AA SLE patients.

Methods: Our retrospective cohort study of 113 AA SLE patients addressed the hypothesis that APOL1 variants increase the risk of avascular necrosis. Subjects were recruited from three high volume urban SLE clinical sites.  This IRB-approved study included patients over 18 years of age, of self-reported AA ancestry, meeting at least four of the American College of Rheumatology (ACR) revised criteria for SLE. PCR/sequencing was used to stratify subjects by APOL1 genotype. Medical charts including clinical notes and imaging reports were reviewed for documentation of avascular necrosis. Subjects were stratified into groups with zero, one or two risk alleles. Association between presence of AVN and APOL1 risk allele, basic demographic characteristics and duration of SLE disease were evaluated using logistic regression analysis via R statistical software.

Results: The frequencies of the G0, G1, and G2 alleles were 0.6, 0.22, and 0.18 respectively. Of the 113 patients 18 (16%) had documented AVN. Higher proportion of patients with documented AVN n = 16 (89%) had at least one risk APOL1 allele present vs those without AVN n = 59 (62%). There were no significant differences for age and gender between patients with and without AVN. Presence of one APOL1 allele trended towards increased risk of AVN (p=0.081), having two APOL1 risk alleles (p=0.016) and longer disease duration (p< 0.001) were associated with increased risk of AVN. Having one APOL1 risk allele (p=0.011) or two risk APOL1 risk alleles (p=0.003) and disease duration (p< 0.001) were significant when adjusted for age in multivariable logistic model. APOL1 variant alleles were associated with AVN in a dose dependent relationship with homozygotes variant carriers having the highest prevalence (OR 31.4 95% CI 3.25-303.63, p=0.003). BMI, average disease activity, corticosteroid use, presence of nephritis and ESRD were not associated with presence of AVN.

Conclusion: Our analysis suggests higher risk of avascular necrosis among African American SLE patients who are carriers of APOL1 risk allele. Given the high allelic frequencies of these variants in African Americans, this relationship may underpin the observed association of AVN with Black race. Further work is necessary to uncover the mechanism of this association. 

Figure 1: APOL1 risk alleles were associated with AVN with homozygotes variant carriers having the highest prevalence -OR 31.4 95% CI 3.25-303.63, p=0.003-.

Figure 2: Longer disease duration was associated with increased risk of AVN -p<0.001-.


Disclosure: K. Yip, None; E. Efuni, None; Y. Qian, None; R. Clancy, None; J. Buyon, Bristol Myers Squibb, 5, Exagen Diagnostics, 2; A. Blazer, None.

To cite this abstract in AMA style:

Yip K, Efuni E, Qian Y, Clancy R, Buyon J, Blazer A. Avascular Necrosis Is Associated with APOL1 Variants in African Americans with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/avascular-necrosis-is-associated-with-apol1-variants-in-african-americans-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/avascular-necrosis-is-associated-with-apol1-variants-in-african-americans-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology